CED Member Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office has issued Notices of Allowance for five U.S. Patent Applications: 12/879,428, 13/246,263, 13/245,650, 13/246,355 and 13/246,376 (“the Applications”). The allowed claims relate to a broad set of genome engineering methods and materials. These methods constitute multiple aspects of Precision’s genome engineering technology known as the Directed Nuclease Editor or DNE.
“We are thrilled that twelve of our patent applications in the U.S. and Europe have now been allowed”
The allowance of the claims of the Applications follow Precision’s recently allowed claims from U.S. Patent Applications 13/246,270, 13/246,346, 13/246,380, and European Patent Application 10 191 888 and further augments Precision’s ability to protect its proprietary DNE technology, features of which are already covered under claims of Precision’s U.S. Patent Nos. 8,021,867, 8,119,361 and 8,119,381 (“the Patents”). Precision previously announced that it has asserted the Patents against Cellectis SA in three patent infringement lawsuits pending in the U.S. District Court for the Eastern District of North Carolina.
“We are thrilled that twelve of our patent applications in the U.S. and Europe have now been allowed,” stated Jeff Smith, Precision BioSciences’ Chief Science Officer. “It is deeply satisfying that our innovative contributions to the field of genome engineering will be so well protected upon issuance of these patents.”
